All In Biotech

Drug Trial Radar · NCT02668172

Pasireotide LAR and Pegvisomant Study in Acromegaly

Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant

Last checked: Nov 20, 2026Latest source record: Aug 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Actual

Start

Aug 2015

Primary completion

Mar 2017

Study completion Jun 2017

Sponsor

Lead sponsor
Erasmus Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis
First posted
Jan 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of long-acting Somatostatin analogs (LA-SSAs) and PEGV.

Conditions

  • Acromegaly

Interventions

  • Pasireotide LAR 60 mgDrug

    as mono-therapy or in combination with pegvisomant

  • PegvisomantDrug

    only in combination with pasireotide LAR

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with normalized IGF1 levels at 24 weeks in the pasireotide LAR monotherapy group and in the pasireotide LAR combined with pegvisomant groupTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Erasmus Medical Center

    Rotterdam, South Holland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.